Joshua Foukas Sells 3,791 Shares of USANA Health Sciences (NYSE:USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider Joshua Foukas sold 3,791 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $19.82, for a total value of $75,137.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Joshua Foukas also recently made the following trade(s):

• On Friday, February 20th, Joshua Foukas sold 4,461 shares of USANA Health Sciences stock. The stock was sold at an average price of $21.34, for a total transaction of $95,197.74.

USANA Health Sciences Trading Down 2.4%

Shares of NYSE USNA opened at $19.00 on Friday. The firm has a 50 day moving average of $18.45 and a 200 day moving average of $19.70. The firm has a market capitalization of $350.74 million, a price-to-earnings ratio of 40.43, a price-to-earnings-growth ratio of 0.75 and a beta of 0.77. USANA Health Sciences, Inc. has a 12-month low of $16.60 and a 12-month high of $38.32.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.17. The company had revenue of $250.22 million during the quarter, compared to analyst estimates of $240.99 million. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Sell-side analysts predict that USANA Health Sciences, Inc. will post 2.12 EPS for the current year.

Key USANA Health Sciences News

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: USANA reported a strong Q1 result, with earnings per share coming in well above expectations and revenue also beating estimates, reinforcing the view that the business is still generating better-than-expected profitability. USANA Health Sciences, Inc. Just Recorded A 78% EPS Beat: Here’s What Analysts Are Forecasting Next
• Positive Sentiment: Sidoti raised its FY2026 EPS estimate for USANA, a sign that analysts are becoming more optimistic about the company’s earnings outlook. Sidoti EPS estimate increase
• Positive Sentiment: USANA was upgraded to Zacks Rank #2 (Buy), which may support near-term buying interest as the stock screens better on earnings-estimate momentum. USANA Health (USNA) Upgraded to Buy: What Does It Mean for the Stock?
• Neutral Sentiment: USANA received a USA TODAY Top Workplaces award, which is a positive branding and culture headline but is unlikely to materially affect earnings by itself. USANA’s People-First Culture Earns Spot on USA TODAY Top Workplaces List
• Neutral Sentiment: An insider sale by Joshua Foukas may create some caution, but the transaction was relatively small and does not necessarily signal a fundamental problem. Joshua Foukas insider sale

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. National Bank of Canada FI lifted its stake in shares of USANA Health Sciences by 166.6% during the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after buying an additional 1,201 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of USANA Health Sciences by 382.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,398 shares of the company’s stock valued at $73,000 after buying an additional 1,901 shares in the last quarter. Parallel Advisors LLC lifted its stake in shares of USANA Health Sciences by 1,354.3% during the 4th quarter. Parallel Advisors LLC now owns 3,854 shares of the company’s stock valued at $76,000 after buying an additional 3,589 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of USANA Health Sciences by 52.9% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,834 shares of the company’s stock valued at $106,000 after buying an additional 1,327 shares in the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in shares of USANA Health Sciences during the 3rd quarter valued at $120,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Analyst Ratings Changes

USNA has been the subject of several analyst reports. Wall Street Zen lowered USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 22nd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research note on Friday, March 27th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, USANA Health Sciences has an average rating of “Reduce”.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.